Fulvestrant (Faslodex®) demonstrates clinical benefit in heavily pretreated postmenopausal women with advanced breast cancer:: a single-center experience.

被引：0
|
作者：
Franco, S
Perez, A
Tan-Chiu, E
Frankel, C
Vogel, C
机构：
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2003年 / 82卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
439
引用
收藏
页码：S105 / S105
页数：1
相关论文
共 50 条
  • [31] Fulvestrant in heavily pretreated patients with advanced breast cancer: A Belgium cooperative study.
    Neven, P.
    Paridaens, R.
    Pelgrims, G.
    Martens, M.
    Bols, A.
    Goeminne, J. C.
    Vindevoghel, A.
    Demol, J.
    Stragier, B.
    De Greve, J.
    Schallier, D.
    Van Den Weyngaert, D.
    Becquart, D.
    Borms, M.
    Cocquyt, V
    Van Den Broecke, R.
    Selleslags, J.
    Awada, A.
    Dirix, L.
    Van Dam, P.
    Azerad, M. A.
    Vandenhoven, G.
    Christianes, M. R.
    Vergote, I
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S195 - S195
  • [32] Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer patients
    Amir, E.
    Freedman, O. C.
    Chia, S.
    Petrella, T.
    Dent, S.
    Tonkin, K.
    Ahmad, I.
    Rayson, D.
    Dranitsaris, G.
    Clemons, M.
    BREAST CANCER RESEARCH, 2009, 11 : S19 - S19
  • [33] Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer
    John F. R. Robertson
    M. P. Harrison
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 346 - 348
  • [34] Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer patients
    E Amir
    OC Freedman
    S Chia
    T Petrella
    S Dent
    K Tonkin
    I Ahmad
    D Rayson
    G Dranitsaris
    M Clemons
    Breast Cancer Research, 11
  • [35] Fulvestrant ('Faslodex®') is effective in advanced breast cancer in postmenopausal patients with visceral metastases:: comparison with anastrazole.
    Mauriac, L
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 289 - 289
  • [36] Fulvestrant (faslodex) in women with advanced breast cancer after progression on prior anti-estrogenic therapy:: Our experience
    Fusco, O.
    Malugani, F.
    Menatti, E.
    Berardi, E.
    Fiumano, M.
    Visini, M.
    Ciotti, R.
    Ardizzoia, A.
    Colombo, I
    Villa, F.
    Giordano, M.
    Isa, L.
    Comande, M.
    Bertolini, A.
    ANNALS OF ONCOLOGY, 2006, 17 : XI14 - XI14
  • [37] Clinical and pathological characteristics of triple-negative breast cancer patients: A single-center experience.
    Akdeniz, Aydan
    Yalcin, Selim
    Rahatli, Samed
    Kucukoztas, Nadire
    Yagmurdur, Mahmut Can
    Dizdar, Omer
    Altundag, Ozden
    Ozyilkan, Ozgur
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre
    Cheung, KL
    Owers, R
    Robertson, JFR
    ENDOCRINE-RELATED CANCER, 2006, 13 (01) : 251 - 255
  • [39] Trastuzumab in the treatment of advanced breast cancer: Single-center experience
    Mrsic, M
    Grgic, M
    Budisic, Z
    Podolski, P
    Bogdanic, V
    Labar, B
    Jakic-Razumovic, J
    Restek-Samarzija, N
    Gosev, M
    ANNALS OF ONCOLOGY, 2001, 12 : 95 - 96
  • [40] Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer
    Chedid, S
    Rivera, E
    Frye, DK
    Ibrahim, N
    Esteva, F
    Valero, V
    Hortobagyi, G
    Mettinger, KL
    Cristofanilli, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (04) : 540 - 544
12345